Skip to main content
SpringerLink
Log in

Angiographic endpoints in progression trials

  • Chapter
Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 180))

Summary

The use of different angiographic criteria represents one of the reasons why the results of angiographic trials are difficult to compare. In principle, this is an avoidable problem and therefore a serious attempt at standardization should be made. This chapter reviews the criteria which have been used in trials using quantitative coronary angiography and presents a proposal for standardization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 1993;119:969–76.

    PubMed  CAS  Google Scholar 

  2. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.

    Article  PubMed  CAS  Google Scholar 

  3. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975–90.

    PubMed  CAS  Google Scholar 

  4. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–12.

    Article  PubMed  CAS  Google Scholar 

  5. Pitt B, Mancini GB, Ellis SG, Rosman HS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) [abstract]. J Am Coll Cardiol. 1994;23 Special issue: 131A.

    Google Scholar 

  6. The MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) [published erratum appears in Lancet. 1994;344:762]. Lancet. 1994;344:633–8.

    Article  Google Scholar 

  7. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959–68.

    PubMed  CAS  Google Scholar 

  8. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994;344:1182–6.

    Article  PubMed  CAS  Google Scholar 

  9. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86:1–11.

    PubMed  CAS  Google Scholar 

  10. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563–9.

    Article  PubMed  CAS  Google Scholar 

  11. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–40.

    PubMed  CAS  Google Scholar 

  12. Quinn TG, Alderman EL, McMillan A, Haskell W. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cardiol. 1994;24:900–8.

    Article  PubMed  CAS  Google Scholar 

  13. Bruschke AV, Padmos I, Buis B, Van Benthem A. Arteriographic evaluation of small coronary arteries. J Am Coll Cardiol. 1990;15:784–9.

    Article  PubMed  CAS  Google Scholar 

  14. Reiber JH, Jukema W, van Boven A, van Houdt RM, Lie KI, Bruschke AV. Catheter sizes for quantitative coronary arteriography. Cathet Cardiovasc Diagn. 1994;33:153–5; discussion 156.

    Article  PubMed  Google Scholar 

  15. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530–8.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. V. G. Bruschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Jukema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. J. Van Boven
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. T. Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. H. C. Reiber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. H. Zwinderman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, University Hospital Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Albert V. G. Bruschke

  2. Department of Diagnostic Radiology and Nuclear Medicine, University Hospital Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Johan H. C. Reiber

  3. University of Amsterdam, The Netherlands

    K. I. Lie

  4. Interuniversity Cardiology Institute of The Netherlands, P.O. Box 19258, 3501 DG, Utrecht, The Netherlands

    Hein J. J. Wellens

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Bruschke, A.V.G., Jukema, J.W., Van Boven, A.J., Bal, E.T., Reiber, J.H.C., Zwinderman, A.H. (1996). Angiographic endpoints in progression trials. In: Bruschke, A.V.G., Reiber, J.H.C., Lie, K.I., Wellens, H.J.J. (eds) Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis. Developments in Cardiovascular Medicine, vol 180. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0143-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0143-8_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6551-1

  • Online ISBN: 978-94-009-0143-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation